Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Summary of Product Characteristics Xolair®. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/000606/WC500057298.pdf
2. Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S (2014) Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2:525–536
3. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Riviera I, Zu J, Rosen KE, Eisner MD, Wong DA, Busse W (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154:573–582
4. Braunstahl G-J, Chlumský J, Peachey G, Chen C-W (2013) Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 9:47
5. Deschildre A, Marguet C, Langlois C, Pin I, Rittie J-L, Derelle J, Taam RA, Fayon M, Brouard J, Dubus JC et al (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 46:856–859
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunobiologicals and ocular surface disease;Current Opinion in Allergy & Clinical Immunology;2022-10
2. Therapeutic Targets in Allergic Conjunctivitis;Pharmaceuticals;2022-04-28